Pfizer (PFE) provided an update on its coronavirus treatments and vaccines in a slide presentation.
The updated presentation contains information about the processes in action, which includes:
- studies ongoing for potential Delta and Beta-specific vaccines;
- developing at risk a potential vaccine tailored to Omicron spike sequence;
- ability to develop/produce at scale tailor-made vaccine in ˜100 days if needed;
- PAXLOVID developed with mutations in mind, with the goal of avoiding treatment resistance.
With regard to PAXLOVID, Pfizer's oral antiviral drug, the company is projecting to produce 80 mln treatment courses for the COVID-19 pill in 2022. That is up from the previously projected 50 mln.
Pfizer also said that it expects revenues of $31 bln from the sales of 1.9 bln doses of its vaccine Comirnaty in 2022 based on contracts signed as of mid-November 2021.